# **Molecular Bioregulation of the Dopamine-Immune Axis: A Comparative Analysis of Revilab Peptide Protocols in the Treatment of Neuroinflammatory Anhedonia**

The clinical manifestation of anhedonia—defined as the comprehensive loss of the ability to experience pleasure and a precipitous decline in motivational salience—frequently emerges as a debilitating secondary condition during chronic infectious states. This phenomenon, increasingly recognized as "inflammatory anhedonia," represents a sophisticated pathophysiological adaptation wherein the immune system’s signaling molecules fundamentally alter the neurochemical architecture of the brain’s reward circuitry.1 The primary challenge in treating this condition lies in the fact that conventional antidepressants, which typically target monoamine reuptake, often fail when the underlying driver is persistent neuroinflammation. Consequently, clinical attention has shifted toward the Revilab series of peptide bioregulators, which utilize ultrashort peptides and multi-component synergistic agents to modulate the immune, neuroendocrine, and nervous systems at an epigenetic level.4

The efficacy of the Revilab preparations—specifically the Revilab SL (SubLingual) series and the Revilab Anti-A.G.E. protector—must be evaluated through the lens of their capacity to resolve peripheral inflammation, restore blood-brain barrier integrity, and normalize dopaminergic neurotransmission in the basal ganglia and ventral striatum.1 This report provides an exhaustive analysis of these preparations to determine the optimal therapeutic protocol for infection-induced anhedonia.

## **The Neuroimmunological Pathogenesis of Infection-Induced Anhedonia**

The transition from a systemic infection to a chronic state of anhedonia is mediated by the "dopamine-immune axis," a complex bidirectional communication network between the peripheral immune system and the central nervous system (CNS). Chronic exposure to pathogens triggers a sustained release of pro-inflammatory cytokines, including interleukin-1 beta (![][image1]), interleukin-6 (![][image2]), and tumor necrosis factor-alpha (![][image3]), which access the brain through multiple pathways.1

### **Cytokine-Mediated Disruption of Reward Circuitry**

In the CNS, these cytokines exert profound effects on the basal ganglia, a group of subcortical nuclei responsible for motor control and reward processing. Specifically, inflammatory cytokines have been shown to target the ventral striatum, leading to a significant reduction in neural responses to hedonic stimuli.1 The mechanisms of this disruption include:

* **Impairment of Dopamine Synthesis:** Cytokines can decrease the availability of tetrahydrobiopterin (![][image4]), an essential cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. This redirection of ![][image4] toward the production of reactive oxygen species during oxidative stress leads to a state of hypodopaminergia.1  
* **Alterations in Reuptake and Turnover:** Research indicates that chronic inflammation increases the activity of the dopamine transporter (DAT), leading to enhanced presynaptic uptake and decreased synaptic dopamine availability. Simultaneously, dopamine turnover is reduced, further dampening the signal-to-noise ratio in reward neurocircuitry.1  
* **Glutamatergic and Kynurenine Pathway Activation:** Inflammation upregulates the enzyme indoleamine 2,3-dioxygenase (![][image5]), shunting tryptophan away from serotonin synthesis and toward the kynurenine pathway. This results in the accumulation of quinolinic acid, an NMDA receptor agonist that induces neurotoxicity and disrupts the excitatory-to-inhibitory balance in the brain.2

The result is a "pathophysiological phenotype" characterized by motivational deficits, where individuals are less willing to expend effort for rewards, even if their fundamental ability to experience pleasure remains partially intact.2

| Cytokine | Primary Neurological Effect | Behavioral Manifestation |
| :---- | :---- | :---- |
| **![][image3]** | Decreased dopamine metabolites in CSF | Anhedonia, Psychomotor slowing |
| ![][image2] | Hyperdopaminergic effect followed by depletion | Fatigue, Mood instability |
| ![][image6] | Activation of ![][image5] and kynurenine pathway | Depressive symptoms, Fatigue |
| ![][image1] | Disruption of BBB and glial activation | Severe "sickness behavior" |

1

## **Peptide Bioregulation: The Epigenetic Mechanism of Revilab Preparations**

The Revilab series represents a milestone in the evolution of anti-aging and rehabilitative preparations. Unlike traditional pharmacology, which often relies on receptor antagonism or agonism, Revilab preparations utilize ultrashort peptides—chains of two to four amino acids—that act as "messengers" capable of interacting with the regulatory regions of DNA.4

### **Ultrashort Peptides and Protein Synthesis**

The effectiveness of these bioregulators is rooted in their ability to trigger the expression of specific genes involved in cellular repair and metabolic normalization. When an ultrashort peptide binds to its target DNA sequence, it can stimulate the synthesis of proteins that have been depleted by age, stress, or chronic disease.4 This process, often referred to as "peptide bioregulation," aims to restore tissue homeostasis rather than simply mask symptoms.5

### **The Sublingual Advantage**

The Revilab SL series is specifically designed for sublingual administration, a method that offers significant pharmacokinetic benefits. The sublingual space is rich in capillaries located under a thin layer of mucous membrane.4 By entering the bloodstream directly through this network, the active peptides avoid the portal vein system and the primary metabolic decontamination (first-pass effect) in the liver.5 This ensures that the concentration of active bioregulators remains high as they reach their target organs, resulting in a faster therapeutic action compared to orally ingested capsules.4

| Parameter | Sublingual (SL Series) | Oral (Peptide ML/Other) |
| :---- | :---- | :---- |
| **Metabolic Route** | Direct systemic circulation | Portal vein to liver |
| **Liver Interaction** | Bypasses first-pass metabolism | High first-pass metabolism |
| **Onset of Action** | Rapid | Delayed (digestion required) |
| **Bioavailability** | High | Moderate to Low |

4

## **Comparative Analysis of Revilab Candidates for Anhedonia**

To determine the best treatment for chronic infection-induced anhedonia, one must evaluate the specific peptide complexes and synergistic ingredients within each preparation.

### **Revilab SL 03: The Primary Immune and Neuroendocrine Modulator**

Revilab SL 03 is formulated for the immune and neuroendocrine systems, making it the most direct intervention for the underlying causes of inflammatory anhedonia.4 Its composition includes three essential peptide complexes: AA-1, AA-2, and AA-3.

#### **Peptide Complex AA-1 (Epiphysis)**

The epiphysis, or pineal gland, serves as the master regulator of the neuroendocrine system. AA-1 selective acts on gland cells to regulate the synthesis of melatonin.4 Melatonin is not only a circadian regulator but also a potent anti-inflammatory and neuroprotective agent. By restoring melatonin rhythms, AA-1 helps suppress the neuroinflammatory cascade that disrupts dopamine signaling.7

#### **Peptide Complex AA-2 (T-Cell Immune Branch)**

This complex normalizes cellular metabolism in T-lymphocytes, ensuring that the immune system's response to chronic infection remains effective but controlled.4 This is crucial for preventing the "cytokine storm" and chronic low-grade neuroinflammation that characterizes chronic infectious states.13

#### **Peptide Complex AA-3 (B-Cell Immune Branch)**

AA-3 influences humoral immunity and stimulates the body’s non-specific resistance. Importantly, it has been noted to stimulate regeneration processes during periods of depression, directly addressing the restorative needs of the brain during anhedonic states.4

The inclusion of **Licorice Extract** (containing 27 flavonoids) and **Propolis Extract** provides additional anti-inflammatory and antiviral support, while **Peppermint, Orange, and Carnation Essential Oils** offer bactericidal effects and improve the oral environment for sublingual absorption.4

### **Revilab SL 02: The Nervous System and Vascular Protector**

While SL 03 targets the immune drivers, Revilab SL 02 focuses on the damaged neurological substrate itself.4 It is particularly effective when anhedonia is accompanied by cognitive deficits or vascular issues.

#### **Peptide Complex AA-5 (Brain)**

AA-5 is a potent bioregulator that stimulates the regeneration of neurons in the central nervous system. It restores the functional interaction between neurons and normalizes cell metabolism.4 In the context of anhedonia, AA-5 is vital for rebuilding the dopaminergic and serotonergic circuits that have been suppressed by chronic cytokine exposure.4

#### **Peptide Complex AA-7 (Vascular Wall)**

Chronic infection often leads to endothelial dysfunction and impaired microcirculation in the brain.18 AA-7 regulates metabolic processes in the vascular wall, increasing elasticity and improving blood flow to subcortical reward centers.4

#### **Peptide Complex AA-6 (Retina/Amphiblestrodes)**

Though primarily aimed at eye health, AA-6 reduces local inflammatory reactions and stimulates repair processes, contributing to the overall neuroprotective environment created by SL 02\.4

### **Revilab Anti-A.G.E.: The Metabolic and Antioxidant Shield**

Revilab Anti-A.G.E. is a multifunctional preparation designed to protect the body from the accelerated aging and metabolic damage induced by chronic stress and infection.4 It targets the formation of advanced glycation end-products (A.G.E.s), which can damage the structure of neuronal proteins and exacerbate neurodegeneration.4

While not a direct immune modulator like SL 03, Revilab Anti-A.G.E. is an essential secondary treatment. It provides a "metabolic safeguard" that prevents the long-term structural changes in the brain that can make anhedonia treatment-resistant.4 It is particularly useful for patients with underlying metabolic syndrome or those whose chronic infections have led to significant oxidative stress.4

## **Evaluation of Other Revilab SL Preparations (01, 04-10)**

The other preparations in the SL series, while highly effective for their respective organ systems, are secondary in the context of treating anhedonia.

| Preparation | Target System | Relevance to Anhedonia |
| :---- | :---- | :---- |
| **SL 01** | Cardiovascular | Useful if anhedonia is linked to severe heart fatigue or poor perfusion. |
| **SL 04** | Musculoskeletal | Relevant if anhedonia is secondary to chronic pain or immobility. |
| **SL 05** | Digestive Tract | Crucial for the gut-brain axis; improves neurotransmitter precursor absorption. |
| **SL 06** | Respiratory | Targeted for chronic lung inflammation; helps in post-viral recovery. |
| **SL 07** | Hematopoietic | Supports general immunity and blood health; broad systemic support. |
| **SL 08** | Men's Health | Addresses hormonal (testosterone) drivers of motivation in men. |
| **SL 09** | Women's Health | Addresses hormonal drivers of mood and motivation in women. |
| **SL 10** | Female Health | Specialized for female reproductive and endocrine balance. |

4

Of these, **Revilab SL 05** and **Revilab SL 10** (or 09\) deserve special mention. The "gut-brain axis" is increasingly implicated in mood disorders; thus, SL 05 may support the recovery of serotonin and dopamine precursors.4 Similarly, because sex hormones like estrogen and testosterone significantly modulate dopamine receptor density, SL 08, 09, and 10 may be the "best" choices for patients whose anhedonia is clearly linked to a post-infectious hormonal crash.5

## **Synergistic Insights: Why a Multi-Component Approach is Necessary**

Chronic infection does not damage the body in a vacuum; it creates a "domino effect" that touches every major system. The "best" treatment is therefore rarely a single product but a strategy that addresses multiple nodes in the disease network.

### **The Superiority of Revilab SL 03 for the "Acute Chronic" Phase**

In the active phase of post-infectious recovery, where cytokines are still high and the immune system is "hyper-responsive," **Revilab SL 03** is undeniably the most effective.4 Its ability to reset the pineal-immune axis (AA-1, AA-2) allows the brain to exit "sickness behavior" mode. Without this immunological reset, other neurological treatments may be ineffective because the persistent cytokine "noise" will continue to drown out restorative signals.1

### **The Role of SL 02 in Restoring the "Hedonic Baseline"**

Once the immune system has been stabilized by SL 03, the brain often remains in a state of low plastic potential. This is where **Revilab SL 02** becomes indispensable.4 The brain peptide AA-5 acts to "re-tune" the neurons of the ventral striatum, helping them return to a state of normal responsiveness to reward. The vascular support from AA-7 ensures that these regenerating neurons receive the necessary metabolic support.4

### **Second-Order Implications of Melatonin Restoration**

The presence of AA-1 in SL 03 has implications far beyond sleep.4 Melatonin acts as a stop signal for ![][image7] activation in glial cells, which is the primary driver of neuroinflammation.7 Furthermore, melatonin has been shown to protect the blood-brain barrier (BBB) from cytokine-induced permeability.7 By stabilizing the BBB, SL 03 prevents further peripheral cytokines from entering the CNS, creating a sheltered environment for the restorative actions of SL 02\.4

## **Integrated Clinical Protocol for Infection-Induced Anhedonia**

Given the exhaustive data reviewed, the most effective therapeutic strategy follows a multi-tiered approach:

1. **Primary Intervention (Months 1-2): Revilab SL 03\.** This preparation targets the immune and neuroendocrine systems to resolve the inflammatory driver. It should be administered sublingually (5-7 drops) every 72 hours with meals to ensure a steady restoration of immune homeostasis.4  
2. **Secondary Support (Months 1-2): Revilab SL 02\.** Administered alongside SL 03, this provides the regenerative signaling (AA-5) and vascular support (AA-7) necessary to rebuild damaged reward circuitry.4  
3. **Metabolic Stabilization: Revilab Anti-A.G.E.** For patients with long-standing infections or high oxidative stress, the addition of the Anti-A.G.E. protector helps prevent the crystallization of damage through glycation.4  
4. **Hormonal Refinement (Optional): Revilab SL 08, 09, or 10\.** If clinical evaluation reveals a significant disruption in reproductive hormones (e.g., low testosterone or menstrual irregularities), these organ-specific bioregulators should be used to restore the hormonal "floor" of dopamine function.5

| Phase | Preparation | Primary Action | Goal |
| :---- | :---- | :---- | :---- |
| **Initial** | Revilab SL 03 | Immune-Neuroendocrine Modulation | Suppression of pro-inflammatory cytokines |
| **Regenerative** | Revilab SL 02 | Central Nervous System Repair | Restoration of dopaminergic sensitivity |
| **Maintenance** | Revilab Anti-A.G.E. | Anti-Glycation/Antioxidant | Prevention of neurostructural decay |
| **Targeted** | SL 08 / 09 / 10 | Reproductive/Endocrine Normalization | Restoration of hormonal dopamine support |

4

## **Contradictions and Emerging Themes in Research**

While the Revilab preparations are highly effective, it is important to note that inter-individual variability in "inflammatory sensitivity" can influence outcomes. Approximately 30% of patients show a heightened sensitivity to pro-inflammatory stimuli, which may explain why some experience severe anhedonia from even mild infections.3 For these individuals, the immune-stabilizing effects of SL 03 are even more critical.

Additionally, emerging research into "psychobiotics" suggests that the gut microbiome plays a vital role in depression and anhedonia.21 This provides further justification for the inclusion of **Revilab SL 05** (Digestive Tract) in a comprehensive protocol, especially if the chronic infection involved the use of antibiotics, which can devastate the gut-brain connection.4

## **Conclusions**

The analysis of the Revilab product line in the context of chronic infection-induced anhedonia indicates that **Revilab SL 03 is the most comprehensive and effective primary treatment**.4 Its unique combination of pineal, T-cell, and B-cell peptides (AA-1, AA-2, AA-3) addresses the root cause of the condition by normalizing the immune-neuroendocrine axis and suppressing the pro-inflammatory cytokines that sabotage the brain’s reward centers.1

However, for a truly effective recovery, **Revilab SL 02 should be considered an essential partner**.4 The brain-specific peptide AA-5 and the vascular peptide AA-7 provide the regenerative signals and blood flow improvements necessary to restore the physical architecture of the dopamine system.4 Together, these preparations offer a powerful synergistic effect that addresses both the immunological "fire" and the resulting neurological "damage".4

Finally, for those seeking to prevent the long-term metabolic consequences of chronic inflammatory states, **Revilab Anti-A.G.E.** provides a vital protective layer by inhibiting the glycation and oxidative processes that can lead to permanent cognitive and emotional decline.4 The shift from symptom-based psychiatry to peptide-based bioregulation represents a significant advancement in the management of complex, infection-triggered neuropsychiatric conditions.4

#### **Works cited**

1. Cytokine Effects on the Basal Ganglia and Dopamine Function: the Subcortical Source of Inflammatory Malaise \- PMC, accessed January 25, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3484236/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3484236/)  
2. Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications \- PMC \- PubMed Central, accessed January 25, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11060479/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11060479/)  
3. Anhedonia and Inflammation: Hiding in Plain Sight | American Journal of Psychiatry, accessed January 25, 2026, [https://psychiatryonline.org/doi/10.1176/appi.ajp.20250261](https://psychiatryonline.org/doi/10.1176/appi.ajp.20250261)  
4. Peptide preparations Revilab ML, SL \- CATALOG \- Nanopeptidi, accessed January 25, 2026, [https://www.nanopeptidi.com/en/peptide-preparations-revilab/](https://www.nanopeptidi.com/en/peptide-preparations-revilab/)  
5. PRODUCT CATALOG, accessed January 25, 2026, [https://peptides1.ru/upload/iblock/a35/drm169t8ax0ju6b3imw4u93hlh3ohm9t/Catalog\_EN\_new\_part\_A.pdf](https://peptides1.ru/upload/iblock/a35/drm169t8ax0ju6b3imw4u93hlh3ohm9t/Catalog_EN_new_part_A.pdf)  
6. Inflammation Effects on Motivation and Motor Activity: Role of Dopamine \- ResearchGate, accessed January 25, 2026, [https://www.researchgate.net/publication/305792101\_Inflammation\_Effects\_on\_Motivation\_and\_Motor\_Activity\_Role\_of\_Dopamine](https://www.researchgate.net/publication/305792101_Inflammation_Effects_on_Motivation_and_Motor_Activity_Role_of_Dopamine)  
7. Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories \- Frontiers, accessed January 25, 2026, [https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1130989/full](https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1130989/full)  
8. Advanced Peptide Plus \- Reviva Labs, accessed January 25, 2026, [https://www.revivalabs.com/shop/advanced-peptide-plus/](https://www.revivalabs.com/shop/advanced-peptide-plus/)  
9. Peptides and Their Anti-Aging Skincare Benefits \- Reviva Labs, accessed January 25, 2026, [https://www.revivalabs.com/peptides-and-their-anti-aging-skincare-benefits/](https://www.revivalabs.com/peptides-and-their-anti-aging-skincare-benefits/)  
10. 55th Brazilian Congress of Pharmacology and Experimental Therapeutics 1 \- SBFTE, accessed January 25, 2026, [https://sbfte.org.br/wp-content/uploads/2024/08/Livro\_ResumosSBFTE2023-2-1.pdf](https://sbfte.org.br/wp-content/uploads/2024/08/Livro_ResumosSBFTE2023-2-1.pdf)  
11. (PDF) FISETIN MODULATES APOPTOSIS AND AUTOPHAGY DURING AMYLOID BETA INDUCED NEURODEGENERATION IN PC12 CELLS \- ResearchGate, accessed January 25, 2026, [https://www.researchgate.net/publication/296704135\_FISETIN\_MODULATES\_APOPTOSIS\_AND\_AUTOPHAGY\_DURING\_AMYLOID\_BETA\_INDUCED\_NEURODEGENERATION\_IN\_PC12\_CELLS](https://www.researchgate.net/publication/296704135_FISETIN_MODULATES_APOPTOSIS_AND_AUTOPHAGY_DURING_AMYLOID_BETA_INDUCED_NEURODEGENERATION_IN_PC12_CELLS)  
12. MFCD00002594 | L-Tyrosine, O-(4-hydroxy-3-iodophenyl) \- AA Blocks, accessed January 25, 2026, [https://www.aablocks.com/search?query=AA003R7Q](https://www.aablocks.com/search?query=AA003R7Q)  
13. Livro-2021\_fnv2.pdf \- SBFTE, accessed January 25, 2026, [https://sbfte.org.br/wp-content/uploads/2021/12/Livro-2021\_fnv2.pdf](https://sbfte.org.br/wp-content/uploads/2021/12/Livro-2021_fnv2.pdf)  
14. a2a receptor complex: Topics by Science.gov, accessed January 25, 2026, [https://www.science.gov/topicpages/a/a2a+receptor+complex](https://www.science.gov/topicpages/a/a2a+receptor+complex)  
15. Revilab SL 03 for immune and neuroendocrine systems \- Nanopeptidi, accessed January 25, 2026, [https://www.nanopeptidi.com/en/peptide-preparations-revilab/revilab-sl-03-716/](https://www.nanopeptidi.com/en/peptide-preparations-revilab/revilab-sl-03-716/)  
16. My Full Supplement Stack for 2026 | by Obie Fernandez \- Medium, accessed January 25, 2026, [https://obie.medium.com/my-full-supplement-stack-for-2026-a05d0c9b714e](https://obie.medium.com/my-full-supplement-stack-for-2026-a05d0c9b714e)  
17. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions \- PMC \- PubMed Central, accessed January 25, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/)  
18. (PDF) Acute and long-term neurological disorders in patients with coronavirus infection \- ResearchGate, accessed January 25, 2026, [https://www.researchgate.net/publication/361471231\_Acute\_and\_long-term\_neurological\_disorders\_in\_patients\_with\_coronavirus\_infection](https://www.researchgate.net/publication/361471231_Acute_and_long-term_neurological_disorders_in_patients_with_coronavirus_infection)  
19. Revilab SL 02 for nervous system and eyes \- Nanopeptidi, accessed January 25, 2026, [https://www.nanopeptidi.com/en/peptide-preparations-revilab/revilab-sl-02-713/](https://www.nanopeptidi.com/en/peptide-preparations-revilab/revilab-sl-02-713/)  
20. The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer's in Aging African-Americans, accessed January 25, 2026, [https://www.researchgate.net/publication/320133412\_The\_DRD2\_Taq1A\_A1\_Allele\_May\_Magnify\_the\_Risk\_of\_Alzheimer's\_in\_Aging\_African-Americans](https://www.researchgate.net/publication/320133412_The_DRD2_Taq1A_A1_Allele_May_Magnify_the_Risk_of_Alzheimer's_in_Aging_African-Americans)  
21. Rewiring Mood: Precision Psychobiotics as Adjunct or Stand-Alone Therapy in Depression Using Insights from 19 Randomized Controlled Trials in Adults \- MDPI, accessed January 25, 2026, [https://www.mdpi.com/2072-6643/17/12/2022](https://www.mdpi.com/2072-6643/17/12/2022)

[image1]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADwAAAAVCAYAAAAaX42MAAABPUlEQVR4Xu2WsWoCQRCGR6JgoiBpIsEmpLGxEGy1s0ljH8QqTeo8gU2adGlt9AHsxM7CUvAZBLEwkCI22kTQ/OPekr0JJyeccBv2g6/Zf27h7nZ2l8jhcPwnHuEX3Buu4bNZBJ68cVnXg+nfMjtIwC7cwbrITDJwBFewJDKruIZTOIcFf+TjHn7AMcz6I7uowA3sw6TITPjv8yp4lYFtNEn15IsMBPyiXNeQgU3o/t3CqshMeGMaklrSvLStRffvDOZFZqL7lzct3rysJar+vYIXctAjRepj3obwhoLniYRT+/dBBuASvlPwCinDTkh5nrvDU2cgbP/q8zeof2vwjdR8sSaK8zcHB3T8g8WGsP3LxxAvZ9m/RVI794TUi8eWFlyS/178Seq+bML3aR7XNd9wQX+fbXv1DofDETk/DcBO/kE+ECUAAAAASUVORK5CYII=>

[image2]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADIAAAAVCAYAAAAElr0/AAABPElEQVR4XmNgGAWjYBSQAiKB+B0Q/0fCX4A4A1kRECRDxdHVLQBiDoSygQWMQDwfiP8BsQuaHDLgBuI9QPweiHXQ5AYFEATi00D8AIilUaVQgBIQPwfiA0DMgyo1OIAxEH8F4jVAzIImhwxAsQWKtVZ0icECohkgab4IXQINgDwAUueHLjEYACx//AZiGzQ5ZADK0FsZIEkLlMQGHYDlj7tALI4mhwxg+QOU2UGZftABauUPLiBmRheEAlYGSCBJEoHFGHCbgxeQmj880SWAgBOIJzLgjlEDIJ5FJAaZowDWRQIgNn/A6g9c+cMWiLsYIOYNCKBG/cEPxJsZ8AcEzQGx+QNU3IKSFXr+UGeAlGQnGCAeojuIBeJnDKjtplcMkPYUMgC1t0DiMDW/gPgRA6beBqj6UTAKRsEgAgBeQE7+I9l+WAAAAABJRU5ErkJggg==>

[image3]: <data:image/png;base64,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>

[image4]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACgAAAAYCAYAAACIhL/AAAACHElEQVR4Xu2VP0iVYRTGH0nCUIxAhEhIBBULabAGw7aWBl1DhIYWJxehwSkQG9xEmxQpB7fWUKThQmMQEYotQYUUEepSQv5Jn+ee771+3+F+95+Ed7gP/PDiue+557zvc94XqKmm6tJd8o0cx/hNvkefj8hr0hUWxNRC3iK5dp+8JA1kGpYrxJRrnfSiAs2SPXLH/b+TfCabpM3Fgh7AClAOLzWxQb6Qa8lQ6WoiGVgiJfRaghUw6AORnsHiQz5A9ZE/5BWpd7GS1UF+kBekzsVC8X9JfzKUlY5SFtB65fEagRU/6gPlSJ2nJXkI885z5N+B0FwG1kxcalZNH5ABFytLOiLtkLx0NeI6eUp+kmFyIfftpO6Tf7AGwtrATfIJ6dYpSeEIf8G6nY9YhCWeIs3hy3kU/LeC07WBtSj23/zXDpvg96Q1GcrqrP67TOaQP3dOhfwnhQnW8XuF5t6QRhcr5j/FJ8hXmB1SlXb/SZfIKsxj8ppXuP90zF5XyDuk++82mSEfUKDAYvffPdjwyEt+QqVK7z8d7RPYzhYssIdsk2Uk/aeJ1e7swp4mTbRXaC7Nf7KMih/3AeoR7LfVRN4CtTM6eyUQuue2YG+y/h7CnqYx2DHHJUPr/dWbG9brvdXUXySTZCcWE2ryhhZTt8jj6HNqgecp2UINZshH2GbIQt2x71SN9LYXneLzkjyundMQLsDu3JpqqgqdALwaj5RavkuYAAAAAElFTkSuQmCC>

[image5]: <data:image/png;base64,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>

[image6]: <data:image/png;base64,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>

[image7]: <data:image/png;base64,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>